WallStreetZenWallStreetZen

NASDAQ: BDRX
Biodexa Pharmaceuticals PLC Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Be the first to know when Wall Street analysts revise their BDRX stock forecasts and price targets.

Forecast return on equity

Is BDRX forecast to generate an efficient return?

Company
0%
Industry
-20.5%
Market
135.76%
BDRX's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is BDRX forecast to generate an efficient return on assets?

Company
0%
Industry
-25.98%
BDRX is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

BDRX earnings per share forecast

What is BDRX's earnings per share in the next 2 years based on estimates from 3 analysts?

Avg 1 year Forecast
$0.00
Avg 2 year Forecast
$0.00

BDRX revenue forecast

What is BDRX's revenue in the next 2 years based on estimates from 3 analysts?

Avg 1 year Forecast
$0.0
Avg 2 year Forecast
$0.0

BDRX vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
SCNI$0.33N/AN/A
AKTX$13.40$33.50+150.00%Strong Buy
NCNA$1.95N/AN/A
BDRX$3.03N/AN/A
ADTX$0.01N/AN/A
View Top Biotech Stocks

Biodexa Pharmaceuticals Stock Forecast FAQ

What is BDRX's earnings growth forecast for 2026-2027?

(NASDAQ: BDRX) Biodexa Pharmaceuticals's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 106.18%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 1,344.48%.

Biodexa Pharmaceuticals's earnings in 2026 is -$8,512,000.On average, 3 Wall Street analysts forecast BDRX's earnings for 2026 to be $0, with the lowest BDRX earnings forecast at $0, and the highest BDRX earnings forecast at $0.

In 2027, BDRX is forecast to generate $0 in earnings, with the lowest earnings forecast at $0 and the highest earnings forecast at $0.

If you're new to stock investing, here's how to buy Biodexa Pharmaceuticals stock.

What is BDRX's revenue growth forecast for 2026-2027?

(NASDAQ: BDRX) Biodexa Pharmaceuticals's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 22.72%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 23.07%.

Biodexa Pharmaceuticals's revenue in 2026 is $0.On average, 3 Wall Street analysts forecast BDRX's revenue for 2026 to be $0, with the lowest BDRX revenue forecast at $0, and the highest BDRX revenue forecast at $0.

In 2027, BDRX is forecast to generate $0 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $0.

What is BDRX's forecast return on assets (ROA) for 2026-2027?

(NASDAQ: BDRX) forecast ROA is 0%, which is higher than the forecast US Biotechnology industry average of -25.98%.

What is BDRX's Earnings Per Share (EPS) forecast for 2026-2027?

(NASDAQ: BDRX) Biodexa Pharmaceuticals's current Earnings Per Share (EPS) is -$0.67. On average, analysts forecast that BDRX's EPS will be $0.00 for 2026, with the lowest EPS forecast at $0.00, and the highest EPS forecast at $0.00. In 2027, BDRX's EPS is forecast to hit $0.00 (min: $0.00, max: $0.00).

What is BDRX's forecast return on equity (ROE) for 2026-2027?

(NASDAQ: BDRX) forecast ROE is 0%, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.